Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.
Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.
Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
Private practice with Dr Seth BilazarianView all posts »
Adopting rivaroxaban (Xarelto): The pros and the consNov 8, 2011 16:28 EST
Now that Xarelto has been FDA approved and is becoming available in pharmacies across the US, how should we adopt this new drug?
To read my comparative review of the literature, download this slideset.
- Anti-Thrombotic Therapy in AF: Warfarin, Dabigatran (Pradaxa) and now Rivaroxaban (Xarelto)
- FDA approves rivaroxaban for stroke prevention in AF patients
- Xarelto prescribing information